Join a clinical trial
Clinical trials are research studies involving people. They test ways to treat and prevent disease and are the gold standard tests for decisions on whether a treatment works and if it is more effective than an alternative treatment.
We conduct trials into chronic respiratory conditions, including asthma, COPD, bronchiectasis, idiopathic pulmonary fibrosis (IPF) and cystic fibrosis.
Below lists a number of clinical trials you may be eligible for. Each trial is different, so please read our FAQs to find out more.
Flu Vaccine – Healthy Volunteers
This study aims to evaluate an investigational vaccine against diseases caused by respiratory syncytial virus (RSV) when given at the same time as the approved annual influenza vaccine.
- Healthy adults aged 65 to 85 years
- Willing and able to follow a study treatment plan of scheduled study visits, lab tests and other study
- Procedures for the duration of the study, approximately 12 months
You will be required to attend 1 longer visit to Sir Charles Gairdner Hospital to receive the investigational vaccine or placebo and also the annual approved influenza vaccine. You will then need to attend 4 more short visits over the next 12 months.
The study aims to evaluate the effectiveness and safety of Tezepelumab in patients with asthma.
- Aged between 18-80 with a diagnosis of asthma made by a doctor
- Use of two asthma inhalers daily
- At least two asthma flare-ups in the last 12 months
- Current smokers excluded
You will be required to attend up to 17 visits to Sir Charles Gairdner Hospital for approximately 16 months.
Alpha1 Antitrypsin Deficiency
- 18- 70 years old
- Diagnosis of Alpha 1 Antitrypsin Deficiency with evidence of emphysema.
- No flare up of the chest in the last 5 weeks prior to the first visit.
- No cancer in last 5 years
You will be required to come once a week for 3 years for treatment including health checks to Sir Charles Gairdner Hospital.
CT scans of your lungs will be required on 5 occasions throughout the trial
The study aims to evaluate the effect of inhaled colistimethate sodium (study drug) compared with no study drug on the frequency of exacerbations (chest flare ups) and the number of exacerbation-free days over the 12 month treatment period.
- Aged 18 or over with a diagnosis of non-cystic fibrosis bronchiectasis by CT scan
- At least two flare ups of your bronchiectasis requiring oral antibiotic treatment in the last 12 months (or one requiring intravenous antibiotic treatment in the last 12 months)
- Sputum tested positive for P. Aeuruginosa in the last 12 months
You will be required to attend up to 7 visits to Sir Charles Gairdner Hospital and complete 2 phone calls for up to approximately 14 months.
The aim of this study is to evaluate the effect of CC-90001 in 200 mg tablet and 400 mg tablet, taken once daily compared with a placebo, on lung function after 24 weeks of treatment in patients with Idiopathic Pulmonary Fibrosis (IPF).
- Aged 40 years or older
- Have been diagnosed with IPF within the last 5 years
- Forced Vital Capacity (FVC) ≥45% at screening
- Percent predicted diffusion capacity of the lung for carbon monoxide (DLCO) ≥ 25% and ≤ 90% predicted at Screening
- Able to walk ≥150m during the 6-minute walk test at screening
- Additional inclusion/exclusion criteria apply
You will be required to attend a monthly visit to Sir Charles Gairdner Hospital for approximately 26 months. In the first 6 months, you will receive study treatment or placebo (2:1) in the form of oral tablets. However, after this time you will then enter a 19-month active treatment phase where you will receive either dose of study drug. Participants will continue to receive monthly check-ups with the site’s doctor during this phase
The aim of this study is to evaluate the safety of Pirfenidone Solution for inhalation (AP01) in patients with idiopathic pulmonary fibrosis (ATLAS Study).
- 40 to 90 years of age at screening.
- Clinical symptoms consistent with IPF of ≥ 12 months duration (with or without IPF diagnosis).
- Diagnosis of IPF, no more than 48 months before randomization.
- Forced Vital Capacity between 40% to 90 % predicted at screening DLCO between 30% to 90% at screening.
- Do not have a clinical diagnosis of any connective tissue disease, including but not limited to scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid
- Not eligible for oral pirfenidone and nintedanib due to national formulary restrictions or intolerant to or unwilling to start oral pirfenidone and nintedanib.
You will be required to attend monthly visits to Sir Charles Gairdner Hospital for approximately 6 months and then 3 monthly visits for the second part of the study (13 visits over approximately 19 months). You will receive study treatment in the form of a nebuliser (two different doses). There is no placebo in this trial.